Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia

Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV

(2020) Ping-Ing Lee et al.   JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION

Favipiravir, an anti-influenza drug against life-threatening RNA virus infections

(2020) Kimiyasu Shiraki et al.   PHARMACOLOGY & THERAPEUTICS

Dosing will be a key success factor in repurposing antivirals for COVID‐19

(2020) Patrick F. Smith et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Interferon beta-1b for COVID-19

(2020) Sarah Shalhoub   LANCET

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial

(2020) Ivan Fan-Ngai Hung et al.   LANCET

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

(2020) Joshua Geleris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Drug treatment options for the 2019-new coronavirus (2019-nCoV)

(2020) Hongzhou Lu   BioScience Trends

Type 1 interferons as a potential treatment against COVID-19

(2020) Erwan Sallard et al.   ANTIVIRAL RESEARCH

The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers

(2020) Denis Malvy et al.   PLoS Neglected Tropical Diseases

Type I interferon susceptibility distinguishes SARS-CoV-2 from SARS-CoV.

(2020) Kumari G. Lokugamage et al.   JOURNAL OF VIROLOGY

Favipiravir at high doses has potent antiviral activity in SARS-CoV-2−infected hamsters, whereas hydroxychloroquine lacks activity

(2020) Suzanne J. F. Kaptein et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted

(2017) Thi Huyen Tram Nguyen et al.   PLoS Neglected Tropical Diseases

Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials

(2016) Vincent Madelain et al.   CLINICAL PHARMACOKINETICS

Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea

(2016) Daouda Sissoko et al.   PLOS MEDICINE

Ebola virus dynamics in mice treated with favipiravir

(2015) Vincent Madelain et al.   ANTIVIRAL RESEARCH

Dose regimen of favipiravir for Ebola virus disease

(2015) France Mentré et al.   LANCET INFECTIOUS DISEASES

Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model

(2014) Lisa Oestereich et al.   ANTIVIRAL RESEARCH

Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations

(2014) Mark S. Freedman et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Favipiravir (T-705), a novel viral RNA polymerase inhibitor

(2013) Yousuke Furuta et al.   ANTIVIRAL RESEARCH

Efficacy and safety of interferon beta-1b sc in older RRMS patients—a posthoc analysis of the BEYOND study

(2013) Christian Lampl et al.   JOURNAL OF NEUROLOGY

Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 µg QOD in patients with relapsing-remitting multiple sclerosis: A multicenter, randomized, double-blind, parallel-group pilot study

(2008) B HURWITZ et al.   CLINICAL THERAPEUTICS